Greg H. Guettler, president of Hypertension Diagnostics, said, “We are very pleased with this recognition by Ventures Magazine. We enjoyed considerable success from our marketing of the HDI/PulseWave™ CR-2000 Research System during the last year. This model of our non-invasive proprietary technology is involved in cardiovascular disease and pharmaceutical research trials worldwide largely because of its ability to measure subtle changes in the elasticity of both large and small arteries. Following FDA clearance to market our technology to physicians in late 2000, we began the controlled launch of the CVProfilor^® DO-2020 physician clinic configuration of our proven technology, just nine weeks ago.”

“While we are still early in our marketing effort to introduce the CVProfilor^® into the very large market of physician’s offices, clinics and healthcare facilities throughout the United States, we are encouraged by the progress we have already made to earn a place on Ventures Magazine’s list and by the initial interest that is being expressed in our CVProfilor^® System,” Guettler said.
Ventures Magazine’s list of the 50 Best Performing Small Public Companies in Minnesota was based on performance in five key areas, including revenue growth percentage; dollar revenue growth; income growth percent scaled by revenue; percent growth in total assets; and total return to shareholders. Hypertension Diagnostics was ranked number 38 on Ventures Magazine’s list.
Ventures, the magazine for growing Twin Cities companies, is based in Minneapolis.

About Hypertension Diagnostics
Hypertension Diagnostics, Inc. designs, develops, manufactures and markets proprietary cardiovascular profiling systems for clinical and research applications. These systems carry the Underwriters Labs label and the CE Mark of quality, and they are marketed to physicians, other health care professionals and researchers by a direct sales force and via distributors throughout the world. In addition to providing blood pressure values, the systems non-invasively detect subtle changes in the compliance or elasticity of both large and small arteries which is a unique feature of HDI’s blood pressure waveform analysis technology. The system includes a custom designed Arterial PulseWave™ Sensor to capture waveform data as well as a printer which generates a CVProfile™ Report which can assist physicians in their clinical work.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2000 Annual Report on Form 10-KSB, as amended, under the caption “Risk Factors,” as well as others not now anticipated. 

Hypertension Diagnostics, HDI/PulseWave™ and CVProfilor^® are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Contact: Greg H. Guettler, President